Daisuke Kawakami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daisuke Kawakami has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Daiki Setoyama
Department of Clinical Laboratory, Kyushu University Hospital, Fukuoka 812-8582, Japan
1 shared publication - Dongchon Kang
Institute of Health Data Infrastructure for All, Tokyo, Japan
1 shared publication - Kaori Shinmyozu
Proteomics Support Unit, RIKEN Center for Developmental Biology, Kobe 650-0047, Hyogo, Japan
1 shared publication - Masafumi Ihara
Department of Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan
1 shared publication - Miho Yamauchi
Department of Neurology National Cerebral and Cardiovascular Center Suita Osaka Japan
1 shared publication - Naoki Hayakawa
Department of Pharmacy National Cerebral and Cardiovascular Center Suita Osaka Japan
1 shared publication
Latest Publications
- Open Access
- 25 November 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2195
Fully Automated Quantitative Measurement of Serum Organic Acids via LC-MS/MS for the Diagnosis of Organic Acidemias: Establishment of an Automation System and a Proof-of-Concept Validation
Gas chromatography-mass spectrometry has been widely used to analyze hundreds of organic acids in urine to provide a diagnostic basis for organic acidemia. However, it is difficult to operate in clinical laboratories on a daily basis due to sample pretreatment processing. Therefore, we aimed to develop a fully automated system for quantifying serum organic acids using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pretreatment CLAM-2030 device was connected to an LC-MS/MS system for processing serum under optimized conditions, which included derivatizing serum organic acids using 3-Nitrophenylhydrazine. The derivatized organic acids were separated on a reverse-phase Sceptor HD-C column and detected using negative-ion electrospray ionization multiple reaction monitoring MS. The automated pretreatment-LC-MS/MS system processed serum in less than 1 h and analyzed 19 serum organic acids, which are used to detect organic acidemias. The system exhibited high quantitative sensitivity ranging from approximately 2 to 100 µM with a measurement reproducibility of 10.4% CV. Moreover, a proof-of-concept validation of the system was performed using sera from patients with propionic acidemia (n = 5), methylmalonic acidemia (n = 2), and 3-methylcrotonylglycinuria (n = 1). The levels of marker organic acids specific to each disease were significantly elevated in the sera of the patients compared to those in control samples. The automated pretreatment-LC-MS/MS system can be used as a rapid in-hospital system to measure organic acid levels in serum for the diagnosis of organic acidemias.
- 25 November 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2195
Open AccessFully Automated Quantitative Measurement of Serum Organic Acids via LC-MS/MS for the Diagnosis of Organic Acidemias: Establishment of an Automation System and a Proof-of-Concept Validation
Gas chromatography-mass spectrometry has been widely used to analyze hundreds of organic acids in urine to provide a diagnostic basis for organic acidemia. However, it is difficult to operate in clinical laboratories on a daily basis due to sample pretreatment processing. Therefore, we aimed to develop a fully automated system for quantifying serum organic acids using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pretreatment CLAM-2030 device was connected to an LC-MS/MS system for processing serum under optimized conditions, which included derivatizing serum organic acids using 3-Nitrophenylhydrazine. The derivatized organic acids were separated on a reverse-phase Sceptor HD-C column and detected using negative-ion electrospray ionization multiple reaction monitoring MS. The automated pretreatment-LC-MS/MS system processed serum in less than 1 h and analyzed 19 serum organic acids, which are used to detect organic acidemias. The system exhibited high quantitative sensitivity ranging from approximately 2 to 100 µM with a measurement reproducibility of 10.4% CV. Moreover, a proof-of-concept validation of the system was performed using sera from patients with propionic acidemia (n = 5), methylmalonic acidemia (n = 2), and 3-methylcrotonylglycinuria (n = 1). The levels of marker organic acids specific to each disease were significantly elevated in the sera of the patients compared to those in control samples. The automated pretreatment-LC-MS/MS system can be used as a rapid in-hospital system to measure organic acid levels in serum for the diagnosis of organic acidemias.
- Open Access
- 1 January 2021
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 7 (1) , e12182
Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
Introduction: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. Methods: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly prescribed. Patients underwent the Montreal Cognitive Assessment (MoCA) twice, at a 6‐month interval. Plasma cilostazol, OPC‐13015, OPC‐13213, and OPC‐13217 concentrations were determined using liquid chromatography‐tandem mass spectrometry. Results: MoCA score changes from baseline to the 6‐month visit were positively correlated with ratios of OPC‐13015 to cilostazol and total metabolites ( n = 19, P = .005). Patients with higher ratios of OPC‐13015 (≥0.18, median value; n = 10) had significantly higher MoCA scores ( P = .036) than patients with lower ratios (the ratio n = 9). The absolute value of OPC‐13015 concentration in blood was also higher in patients with preserved cognitive function ( P = .033). Discussion: Blood OPC‐13015 levels may be a predictive biomarker of cilostazol treatment for Alzheimer's disease.
- 1 January 2021
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 7 (1) , e12182
Open AccessConversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
Introduction: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. Methods: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly prescribed. Patients underwent the Montreal Cognitive Assessment (MoCA) twice, at a 6‐month interval. Plasma cilostazol, OPC‐13015, OPC‐13213, and OPC‐13217 concentrations were determined using liquid chromatography‐tandem mass spectrometry. Results: MoCA score changes from baseline to the 6‐month visit were positively correlated with ratios of OPC‐13015 to cilostazol and total metabolites ( n = 19, P = .005). Patients with higher ratios of OPC‐13015 (≥0.18, median value; n = 10) had significantly higher MoCA scores ( P = .036) than patients with lower ratios (the ratio n = 9). The absolute value of OPC‐13015 concentration in blood was also higher in patients with preserved cognitive function ( P = .033). Discussion: Blood OPC‐13015 levels may be a predictive biomarker of cilostazol treatment for Alzheimer's disease.